Showing results (1-10 of 23) with videos related to
Sort By:
Pageof 3
Journal for Immunotherapy of Cancer|April 23, 2022
JAK inhibitors and COVID-19Gabriel Levy, Paola Guglielmelli, Peter Langmuir, et al.Delaware Journal of Public Health|September 1, 2021
Design of Clinical Trials Evaluating Ruxolitinib, a JAK1/JAK2 Inhibitor, for Treatment of COVID-19-Associated Cytokine StormPeter Langmuir, Swamy Yeleswaram, Paul Smith, et al.Annals of Hematology|June 10, 2026
A model to estimate spleen volume from palpated spleen length in patients with myelofibrosisAlbert Assad, Sue Erickson-Viitanen, J E Hamer-Maansson, et al.Clinical Pharmacokinetics|August 10, 2010
Pharmacokinetics of vandetanib in subjects with renal or hepatic impairmentAngelika Weil, Paul Martin, Robert Smith, et al.Clinical Immunology (Orlando, Fla.)|June 26, 2020
Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatmentSwamy Yeleswaram, Paul Smith, Timothy Burn, et al.Leukemia Research|June 14, 2025
A phase 2 study of itacitinib alone or in combination with low-dose ruxolitinib in patients with myelofibrosisMoshe Talpaz, Aaron T Gerds, Roger Lyons, et al.Leukemia & Lymphoma|April 10, 2024
Safety and efficacy of parsaclisib in combination with rituximab, bendamustine + rituximab, or ibrutinib in patients with previously treated B-cell lymphoma: analysis of a phase 1 dose-finding study (CITADEL‑112)Juan-Manuel Sancho, Pau Abrisqueta, Abhijeet Kumar, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 29, 2012
Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR)Jin Soo Lee, Vera Hirsh, Keunchil Park, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2009
Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancerEmer O Hanrahan, Anderson J Ryan, Helen Mann, et al.Hematological Oncology|July 27, 2023
Safety and efficacy of parsaclisib in combination with obinutuzumab and bendamustine in patients with relapsed or refractory follicular lymphoma (CITADEL-102): A phase 1 studyMehdi Hamadani, Morton Coleman, Ralph Boccia, et al.Pageof 3